D-0676-2026 Class II Ongoing

Recalled by Cipla USA, Inc. — Warren, NJ

FDA drug recall D-0676-2026 was initiated by Cipla USA, Inc. on June 29, 2026 and is designated Class II. Reason for recall: cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). The recall status is ongoing. Affected quantity: N/A.

Recall Details

Product Type
Drugs
Report Date
July 8, 2026
Initiation Date
June 29, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-412-02

Reason for Recall

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

Distribution Pattern

USA Nationwide

Code Information

Lot #: 5PB0563, Exp 4/30/2027